Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, April 19, 2023
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
[ Wed, Apr 19th 2023
] - WOPRAI
Serge Belanger Reiterated (ARQT) at Strong Buy and Held Target at $24 on, Apr 19th, 2023
Serge Belanger of Needham, Reiterated "Arcutis Biotherapeutics, Inc." (ARQT) at Strong Buy and Held Target at $24 on, Apr 19th, 2023.
Serge has made no other calls on ARQT in the last 4 months.
There are 4 other peers that have a rating on ARQT. Out of the 4 peers that are also analyzing ARQT, 0 agree with Serge's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Serge
- Nigel Dally of "Morgan Stanley" Maintained at Buy with Decreased Target to $47 on, Wednesday, April 12th, 2023
- Uy Ear of "Mizuho" Reiterated at Strong Buy and Held Target at $61 on, Tuesday, April 11th, 2023
- Gregory Fraser of "Truist Securities" Maintained at Strong Buy with Decreased Target to $45 on, Wednesday, March 29th, 2023
- Vikram Purohit of "Morgan Stanley" Maintained at Buy with Decreased Target to $50 on, Wednesday, March 1st, 2023
